Contineum Therapeutics, Inc. Operating Expenses
Contineum Therapeutics, Inc. (CTNM) reported Operating Expenses of $17.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-30
- Contineum Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $17.43M, a 2.65% decline year-over-year.
- Contineum Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $16.90M, a 6.66% decline year-over-year.
- Contineum Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $17.11M, a 0.40% increase year-over-year.
- Contineum Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $14.93M, a 15.09% increase year-over-year.
- Contineum Therapeutics, Inc. operating expenses for fiscal 2025 was $68.06M, a 33.73% increase from fiscal 2024.
- Contineum Therapeutics, Inc. operating expenses for fiscal 2024 was $50.89M, a 50.03% increase from fiscal 2023.
- Contineum Therapeutics, Inc. operating expenses for fiscal 2023 was $33.92M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.43M 10-Q · filed 2026-07-30 | $34.33M 10-Q · filed 2026-07-30 | $51.45M derived: sum of 3 quarters · filed 2026-07-30 | $66.38M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $16.90M 10-Q · filed 2026-05-05 | $34.02M derived: sum of 2 quarters · filed 2026-05-05 | $48.95M derived: sum of 3 quarters · filed 2026-05-05 | $66.85M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $17.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $32.05M derived: sum of 2 quarters · filed 2026-03-05 | $49.95M derived: sum of 3 quarters · filed 2026-07-30 | $68.06M 10-K · filed 2026-03-05 |
| 2025-09-30 | $14.93M 10-Q · filed 2025-10-30 | $32.83M derived: sum of 2 quarters · filed 2026-07-30 | $50.94M 10-Q · filed 2025-10-30 | $67.99M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $17.90M 10-Q · filed 2026-07-30 | $36.01M 10-Q · filed 2026-07-30 | $53.06M derived: sum of 3 quarters · filed 2026-07-30 | $66.03M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $18.11M 10-Q · filed 2026-05-05 | $35.16M derived: sum of 2 quarters · filed 2026-05-05 | $48.13M derived: sum of 3 quarters · filed 2026-05-05 | $59.08M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $17.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $30.02M derived: sum of 2 quarters · filed 2026-03-05 | $40.97M derived: sum of 3 quarters · filed 2026-03-05 | $50.89M 10-K · filed 2026-03-05 |
| 2024-09-30 | $12.97M 10-Q · filed 2025-10-30 | $23.92M derived: sum of 2 quarters · filed 2025-10-30 | $33.85M 10-Q · filed 2025-10-30 | $43.52M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $10.94M 10-Q · filed 2025-08-05 | $20.87M 10-Q · filed 2025-08-05 | $30.55M derived: sum of 3 quarters · filed 2025-08-05 | $38.62M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $9.93M 10-Q · filed 2025-05-14 | $19.61M derived: sum of 2 quarters · filed 2025-05-14 | $27.68M derived: sum of 3 quarters · filed 2025-05-14 | $38.74M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $9.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $17.75M derived: sum of 2 quarters · filed 2025-03-06 | $28.81M derived: sum of 3 quarters · filed 2025-03-06 | $33.92M 10-K · filed 2025-03-06 |
| 2023-09-30 | $8.07M 10-Q · filed 2024-11-06 | $19.13M derived: sum of 2 quarters · filed 2024-11-06 | $24.25M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $11.06M 10-Q · filed 2024-08-14 | $16.18M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $5.12M 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |